For adults with recent NCIS or high-risk TIA in combination with antiplatelet therapy
A new approach to reducing the risk of ischemic stroke1
Watch FXIa inhibition in action
j
YYMMDD
FXIa inhibition interrupts the feedback loop that amplifies thrombin generation1
Thrombin activates factor XI via a positive feedback loop in the intrinsic pathway, driving thrombus formation and stability.1
FXIa=activated factor XI.
Factor XIa inhibition targets more pathological clotting (thrombosis) with lesser impact on normal clotting response (hemostasis).1
References
- SUNHARBO (asundexian) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; November 2026.
- Fredenburgh JC, Weitz JI. Factor XI as a target for new anticoagulants. Hamostaseologie. 2021;41(2):104-110. doi:10.1055/a-1384-3715
- Heitmeier S, Visser M, Tersteegen A, et al. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J Thromb Haemost. 2022;20(6):1400-1411. doi: 10.1111/jth.15700